The present invention relates to particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide, to a process of making said particles, to pharmaceutical compositions comprising said particles and to method of treating cancers using said pharmaceutical compositions.

The present invention relates to particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide, to a process of making said particles, to pharmaceutical compositions comprising said particles and to method of treating cancers using said pharmaceutical compositions.

Bromocriptine citrate administered to a vertebrate, animal or human, can be used for any purpose including, e.g., the long-term modification and regulation of metabolic disorders, including prediabetes, obesity, insulin resistance, hyperinsulinemia, hyperglycemia and type 2 diabetes mellitus (T2DM) and/or, e.g., the treatment of other medical disorder(s) including immune or endocrine disorders or diseases. Bromocriptine citrate is administered over a limited or extended period at a time of day dependent on re-establishing the normal circadian rhythm of central dopaminergic activity of healthy members of a similar species and sex. Insulin resistance, hyperinsulinemia and hyperglycemia, T2DM, prediabetes, MS or all, can be controlled in humans on a long term basis by such treatment inasmuch as the daily administration of bromocriptine citrate resets neuronal activity timing in the neural centers of the brain to produce long term effects.

Bromocriptine citrate administered to a vertebrate, animal or human, can be used for any purpose including, e.g., the long-term modification and regulation of metabolic disorders, including prediabetes, obesity, insulin resistance, hyperinsulinemia, hyperglycemia and type 2 diabetes mellitus (T2DM) and/or, e.g., the treatment of other medical disorder(s) including immune or endocrine disorders or diseases. Bromocriptine citrate is administered over a limited or extended period at a time of day dependent on re-establishing the normal circadian rhythm of central dopaminergic activity of healthy members of a similar species and sex. Insulin resistance, hyperinsulinemia and hyperglycemia, T2DM, prediabetes, MS or all, can be controlled in humans on a long term basis by such treatment inasmuch as the daily administration of bromocriptine citrate resets neuronal activity timing in the neural centers of the brain to produce long term effects.

A composition may include an alkaline earth metal salt. The alkaline earth metal salt may have an angle of repose less than or equal to about 34. The alkaline earth salt may be used to form a tablet. The tablet may have a friability less than or equal to about 1%. A method of forming an alkaline earth metal salt may include providing a slurry that includes an alkaline earth metal and an organic polyatomic anion, and spray drying the slurry to form a spray dried alkaline earth metal salt. The slurry temperature may be greater than or equal to about 50° C. A method of forming a tablet may include tableting a non-agglomerated alkaline earth metal salt.

A composition may include an alkaline earth metal salt. The alkaline earth metal salt may have an angle of repose less than or equal to about 34. The alkaline earth salt may be used to form a tablet. The tablet may have a friability less than or equal to about 1%. A method of forming an alkaline earth metal salt may include providing a slurry that includes an alkaline earth metal and an organic polyatomic anion, and spray drying the slurry to form a spray dried alkaline earth metal salt. The slurry temperature may be greater than or equal to about 50° C. A method of forming a tablet may include tableting a non-agglomerated alkaline earth metal salt.

A composition may include an alkaline earth metal salt. The alkaline earth metal salt may have an angle of repose less than or equal to about 34. The alkaline earth salt may be used to form a tablet. The tablet may have a friability less than or equal to about 1%. A method of forming an alkaline earth metal salt may include providing a slurry that includes an alkaline earth metal and an organic polyatomic anion, and spray drying the slurry to form a spray dried alkaline earth metal salt. The slurry temperature may be greater than or equal to about 50° C. A method of forming a tablet may include tableting a non-agglomerated alkaline earth metal salt.

A method of extracting nutrients from a plant includes the steps of: pulverizing a water soluble nutrient-based plant part of a first plant material of the plant so as to form a first pulverized plant part; pulverizing a lipid soluble nutrient-based plant part of a second plant material of the plant so as to form a second pulverized plant part; subjecting the first pulverized plant part to a distillation so as to obtain a distillate and a first residue that contains a water soluble nutrient; and immersing the second pulverized plant part in the distillate to form a first mixture followed by distillation of the first mixture, so as to obtain a second residue that contains a lipid soluble nutrient.

A method of extracting nutrients from a plant includes the steps of: pulverizing a water soluble nutrient-based plant part of a first plant material of the plant so as to form a first pulverized plant part; pulverizing a lipid soluble nutrient-based plant part of a second plant material of the plant so as to form a second pulverized plant part; subjecting the first pulverized plant part to a distillation so as to obtain a distillate and a first residue that contains a water soluble nutrient; and immersing the second pulverized plant part in the distillate to form a first mixture followed by distillation of the first mixture, so as to obtain a second residue that contains a lipid soluble nutrient.

The present invention relates to a method for preparing N-[[1-{3-(1,2,3-triazol-1-yl)propyl}piperidin-4-yl]methyl]-4-amino-5-chloro-2-methoxybenzamide, which is a novel benzamide derivative as a 5-HT4 receptor agonist, or a pharmaceutically acceptable salt thereof; to a novel intermediate capable of being used in the preparation of the compounds; and to a method for preparing the same. The preparation methods of the present invention can be useful for mass production since a low-priced reagent and intermediate are used and the number of reaction processes is decreased, thereby saving preparation costs and improving the yield.